Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for scientists. T cells, which are the frontline warriors in the battle against the infections, have been a major focus of research.
Novartis expands Scemblix label to first-line CML patients
Novartis’ chronic myeloid leukemia drug Scemblix will now be available to newly diagnosed patients, the FDA announced on Tuesday. Scemblix was first approved in 2021